Blood sphingolipids in homeostasis and pathobiology

Advances in Experimental Medicine and Biology

Volumn 721, Issue , 2011, Pages 57-66

  Hammad, Samar M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SPHINGANINE; SPHINGOLIPID; VERY LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; CORONARY ARTERY DISEASE; FABRY DISEASE; GAUCHER DISEASE; HEART PROTECTION; HUMAN; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID METABOLISM; LIPIDOMICS; LIPOGENESIS; LIPOPROTEIN METABOLISM; MOLECULAR PATHOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; BLOOD CELLS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; INFLAMMATION; LIPID METABOLISM, INBORN ERRORS; LIPOPROTEINS; LYSOPHOSPHOLIPIDS; SPHINGOLIPIDS; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE;

EID: 80053581281     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0650-1_4     Document Type: Article

References (81)

1. Cuvillier O, Pirianov G, Kleuser B et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996; 381(6585):800-803. (Pubitemid 26243122)
2. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996; 274(5294):1855-1859. (Pubitemid 26424756)
3. Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J 1998; 335 (Pt 3):465-480. (Pubitemid 28515396)
4. Spiegel S, Merrill Jr. A.H. Sphingolipid metabolism and cell growth regulation. FASEB J1996; 10(12):1388-1397. (Pubitemid 26347873)
5. Merrill Jr. A.H. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem 2002; 277(29):25843-25846. (Pubitemid 34967059)
6. Hannun YA, Obeid LM. Ceramide and the eukaryotic stress response. Biochem Soc Trans 1997; 25(4):1171-1175. (Pubitemid 27528557)
7. Vesper H, Schmelz EM, Nikolova-Karakashian MN et al. Sphingolipids in food and the emerging importance ofsphingolipidstonutrition. JNutr 1999; 129(7):1239-1250. (Pubitemid 29304970)
8. Ichi I, Nakahara K, Kiso K et al. Effect of dietary cholesterol and high fat on ceramide concentration in rat tissues. Nutrition 2007; 23(7-8):570-574. (Pubitemid 47002227)
9. Katsikas H, Wolf C. Blood sphingomyelins from two European countries. Biochim Biophys Acta 1995; 1258(2):95-100.
10. Ozbayraktar FB, Ulgen KO. Molecular facets of sphingolipids: mediators of diseases. Biotechnol J 2009; 4(7):1028-1041.
11. Vance DE, Sweeley CC. Quantitative determination of the neutral glycosyl ceramides in human blood. J Lipid Res 1967; 8(6):621-630.
12. Hammad SM, Crellin HG, Wu BX et al. Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages. Prostaglandins Other Lipid Mediat 2008; 85(3-4):107-114.
13. Verheij M, Bose R, Lin XH et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996; 380(6569):75-79. (Pubitemid 26076240)
14. Auge N, Nikolova-Karakashian M, Carpentier S et al. Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase and sphingosine kinase. J Biol Chem 1999; 274(31):21533-21538.
15. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14(5):569-75.
16. Bielawski J, Pierce JS, Snider J et al. Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquidchromatography- tandemmass spectrometry. Methods MolBiol 2009;579:443-467.
17. Hammad SM, Pierce JS, Soodavar F et al. Blood sphingolipidomics in healthy humans: Impact of sample collection methodology. J Lipid Res 2010.
18. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006; 26(4):847-870. (Pubitemid 44716510)
19. Murata N, Sato K, Kon J et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000; 352 Pt 3:809-815. (Pubitemid 32015038)
20. WiesnerP, LeidlK, Boettcher Aet al. Lipid profiling ofFPLC- separatedlipoproteinfractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009; 50(3):574-585.
21. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 2000; 349(Pt2):385-402. (Pubitemid 30465772)
22. Hla T. Sphingosine 1-phosphate receptors. Prostaglandins 2001; 64(1-4):135-142. (Pubitemid 32452287)
23. Argraves KM, Gazzolo PJ, Groh EM et al. High density lipoprotein- associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem 2008; 283(36):25074-25081.
24. Bornfeldt KE, Graves LM, Raines EW et al. Sphingosine-l-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: spatial and temporal modulation of PDGF chemotactic signal transduction. J Cell Biol 1995; 130(1):193-206.
25. Kimura T, Watanabe T, Sato K et al. Sphingosine 1-phosphate stimulates proliferation and migration ofhuman endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem J 2000; 348 Pt 1:71-76. (Pubitemid 30312132)
26. Lee MJ, Thangada S, Claffey KP et al. Vascular endothelial cell adherensjunction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99(3):301-312. (Pubitemid 29519909)
27. Yatomi Y, Yamamura S, Ruan F et al. Sphingosine 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid. J Biol Chem 1997; 272(8):5291-5297. (Pubitemid 27090092)
28. Kontush A, Therond P, Zerrad A et al. Preferential sphingosine-l- phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007; 27(8):1843-1849. (Pubitemid 47207181)
29. Rodriguez C, Gonzalez-Diez M, Badimon L et al. Sphingosine-l-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost 2009; 101(4):665-673.
30. Lucke S, Levkau B. Endothelial functions of sphingosine-l-phosphate. Cell Physiol Biochem 2010; 26(1):87-96.
31. Nixon GF. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol 2009; 158(4):982-993.
32. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator?. Biochim Biophys Acta 2002; 1582(1-3):132-137. (Pubitemid 34634121)
33. Deutschman DH, Carstens JS, Klepper RL et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 2003; 146(1):62-68. (Pubitemid 36851301)
34. Lee MH, Hammad SM, Semler AJ et al. HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes-the role of sphingosine-l-phosphate. J Lipid Res 2010.
35. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 2003; 92(4A):42J-49J.
36. Sparks DL, Davidson WS, Lund-Katz S et al. Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J Biol Chem 1995; 270(45):26910-26917.
37. Curtiss LK, Bonnet DJ, Rye KA. The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. Biochemistry 2000; 39(19):5712-5721. (Pubitemid 30307959)
38. Vedhachalam C, Chetty PS, Nickel M et al. Influence of apolipoprotein (APO) A-I structure on nascent high density lipoprotein (HDL) particle size distribution. J Biol Chem 2010.
39. Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol 2010; 21(4): 305-311.
40. Sattler KJ, Elbasan S, Keul P et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010.
41. Camerer E, Regard JB, Cornelissen I et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest 2009; 119(7):1871-1879.
42. Pappu R, Schwab SR, Cornelissen I et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-l-phosphate. Science 2007; 316(5822):295-298. (Pubitemid 46633109)
43. Venkataraman K, Lee YM, Michaud J et al. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 2008; 102(6):669-676. (Pubitemid 351457860)
44. Yang L, Yatomi Y, Miura Y et al. Metabolism and functional effects of sphingolipids in blood cells. Br J Haematol 1999; 107(2):282-293. (Pubitemid 29530212)
45. Yatomi Y, Igarashi Y, Yang L et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent ofhuman plasma and serum. J Biochem 1997; 121(5):969-973. (Pubitemid 27236918)
46. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4(5):397-407. (Pubitemid 36565571)
47. Hammad SM, Taha TA, Nareika A et al. Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. Prostaglandins Other Lipid Mediat 2006; 79(1-2):126-140.
48. Kumpula LS, Kumpula JM, Taskinen MR et al. Reconsideration of hydrophobic lipid distributions in lipoprotein particles. Chem Phys Lipids 2008; 155(1):57-62.
49. KinnunenPK, Holopainen JM. Sphingomyelinase activity of LDL: alinkbetween atherosclerosis, ceramide and apoptosis?. Trends Cardiovasc Med 2002; 12(1):37-42.
50. Heikela M, Vattulainen I, Hyvonen MT. Atomistic simulation studies of cholesteryl oleates: model for the core oflipoprotein particles. Biophys J 2006; 90(7):2247-2257.
51. Sysi-Aho M, Vehtari A, Velagapudi VR et al. Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profiles. Bioinformatics 2007; 23(13):i519-i528. (Pubitemid 47244439)
52. Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res 2009; 50 Suppl: S91-S96.
53. Cowart LA. Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol Metab 2009; 20(1):34-42.
54. Lahiri S, Futerman AH. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci 2007; 64(17):2270-2284. (Pubitemid 47347954)
55. Liliom K, Sun G, Biinemann M et al. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J 2001; 355(Pt 1):189-197. (Pubitemid 32304249)
56. Merrill AH Jr, Stokes TH, Momin A et al. Sphingolipidomics: a valuable tool for understanding the roles of sphingolipids in biology and disease. J Lipid Res 2009; 50 Suppl: S97-S102.
57. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008; 9(2):162-176. (Pubitemid 351158917)
58. Meyer zu Heringdorf D, Jakobs KH. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 2007; 1768(4):923-940. (Pubitemid 46452543)
59. Mueller RB, Sheriff A, Gaipl US et al. Attraction of phagocytes by apoptotic cells is mediated by lysophosphatidylcholine. Autoimmunity 2007; 40(4):342-344. (Pubitemid 46845536)
60. Tani M, Ito M, Igarashi Y. Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space. Cell Signal 2007; 19(2):229-237. (Pubitemid 44969975)
61. Kolter T, Proia RL, Sandhoff K. Combinatorial ganglioside biosynthesis. J Biol Chem 2002; 277(29): 25859-25862. (Pubitemid 34967063)
62. Hannun YA, Obeid LM. The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters ofthe lipid kind. J Biol Chem 2002; 277(29):25847-25850. (Pubitemid 34967060)
63. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9(2):139-150. (Pubitemid 351158911)
64. Pfeiffer A, Bottcher A, Orso E et al. Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur J Immunol 2001; 31(11):3153-3164. (Pubitemid 33100507)
65. Fujiwaki T, Yamaguchi S, Tasaka M et al. Application ofdelayed extraction-matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in pericardial fluid, peritoneal fluid and serum from Gaucher disease patients. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 776(1):115-123. (Pubitemid 34804349)
66. Fujiwaki T, Tasaka M, Takahashi N et al. Quantitative evaluation of sphingolipids using delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry with sphingosylphosphorylcholine as an internal standard. Practical application to cardiac valves from apatient with Fabry disease. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 832(1):97-102. (Pubitemid 43213015)
67. Abnet CC, Borkowf CB, Qiao YL et al. A cross-sectional study ofhuman serum sphingolipids, diet and physiologic parameters. J Nutr 2001; 131(10):2748-2752. (Pubitemid 32947804)
68. Abnet CC, Borkowf CB, Qiao YL et al. Sphingolipids as biomarkers of fumonisin exposure and risk of esophageal squamous cell carcinoma in china. Cancer Causes Control 2001; 12(9):821-828. (Pubitemid 33010620)
69. Gorska M, Dobrzyn A, Baranowski M. Concentrations of sphingosine and sphinganine in plasma of patients with type 2 diabetes. Med Sci Monit 2005; 11(1):CR35-CR38. (Pubitemid 40116398)
70. Ribar S, Mesaric M, Sedic M. Sphingoid bases as possible diagnostic parameters. Croat Med J 2003; 44(2):165-170. (Pubitemid 36548076)
71. Lieser B, Liebisch G, Drobnik W et al. Quantification of sphingosine and sphinganine from crude lipid extracts by HPLC electrospray ionization tandem mass spectrometry. J Lipid Res 2003; 44(11):2209-2216. (Pubitemid 37509637)
72. Schlitt A, Hojjati MR, von Gizycki H et al. Serum sphingomyelin levels are related to the clearance of postprandial remnant-like particles. J Lipid Res 2005; 46(2):196-200. (Pubitemid 40271082)
73. Jiang XC, Paultre F, Pearson TA et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20(12):2614-2618.
74. Nelson JC, Jiang XC, Tabas I et al. Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study ofatherosclerosis. Am J Epidemiol 2006; 163(10):903-912.
75. Park TS, Panek RL, Rekhter MD et al. Modulation of lipoprotein metabolism by inhibition ofsphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 2006; 189(2):264-272. (Pubitemid 44634484)
76. Hojjati MR, Li Z, Zhou H et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficientmice. JBiol Chem 2005; 280(11):10284-10289. (Pubitemid 40395884)
77. Dong J, Liu J, Lou B et al. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice. J Lipid Res 2006; 47(6):1307-1314. (Pubitemid 43830723)
78. Drobnik W, Liebisch G, Audebert FX et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res 2003; 44(4):754-761. (Pubitemid 37279677)
79. Kontush A, Chapman MJ. Lipidomics as a tool for the study oflipoprotein metabolism. Curr Atheroscler Rep 2010; 12(3):194-201.
80. Schittmayer M, Birner-Gruenberger R. Functional proteomics in lipid research: lipases, lipid droplets and lipoproteins. J Proteomics 2009; 72(6):1006-1018.
81. Alonzi T, Mancone C, Amicone L et al. Elucidation oflipoprotein particles structure by proteomic analysis. Expert Rev Proteomics 2008; 5(1):91-104. (Pubitemid 351287744)